2025-11-13T10:58:52-06:00 2023-12-31 750786316 WEAVER AND TIDWELL LLP ONE PENNSYLVANIA PLAZA STE 2800 NEW YORK NY 10119 990 2023-01-01 133806788 THE OVARIAN CANCER RESEARCH FUND INC OVAR 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 AUDRA L MORAN PRESIDENT & CEO 2122681002 2025-11-13 1 0 TED KIRSHENBAUM CPA P01260796 2126955003 2023 2025-03-06 01:10:19Z X X OVARIAN CANCER RESEARCH ALLIANCE AUDRA L MORAN 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 37798701 0 X WWW.OCRAHOPE.ORG X 1994 NY SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT 19 19 30 4007 0 0 15386443 11556311 283846 438937 755651 1447267 0 0 16425940 13442515 6693567 8117910 0 0 2742095 3064716 0 0 1415702 2026988 2570134 11462650 13752760 4963290 -310245 37659088 39203357 14828822 14720293 22830266 24483064 X OVARIAN CANCER RESEARCH ALLIANCE (OCRA) IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. 0 0 8675579 8117910 OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES. OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. EACH YEAR THERE WILL BE OVER 19,000 NEW CASES OF OVARIAN CANCER IN THE UNITED STATES, AND APPROXIMATELY 14,000 WOMEN WILL DIE OF THE DISEASE. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 418 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 98 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $122 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS, AND ENHANCE PATIENTS' QUALITY OF LIFE. FINALLY,OCRA LAUNCHED A NEW GRANT - HEALTH EQUITY RESEARCH GRANT AND AWARDED 3 IN ITS FIRST YEAR. THESE GRANTS WILL FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE.ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE: SHOWN THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; HELPED EXPLAIN RESISTANCE TO CHEMOTHERAPY; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; EXPLORED THE ROLE OF ESTROGEN IN ANTI-TUMOR IMMUNITY; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; IDENTIFIED A NEW THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER; SHOWN HOW A PARP/IMMUNE THERAPY COMBO SHOWS PROMISE; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; CONFIRMED GENERIC HEART MEDICATION CAN PROLONG SURVIVAL IN OVARIAN CANCER PATIENTS; SHED LIGHT ON HOW OVARIAN CANCER GROWS; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; FOUND THAT A SUBSET OF IMMUNE CELLS PROMOTE TUMOR GROWTH; CLARIFIED WHICH CELL LINES ARE THE BEST FIT FOR USE IN OVARIAN CANCER RESEARCH; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED AREAS OF THE HUMAN GENOME THAT ARE LINKED TO INCREASED RISK FOR OVARIAN CANCER; EVALUATED NEW EXPERIMENTAL MODELS TO ADVANCE OVARIAN CANCER RESEARCH; REVEALED HOW COMBINING TARGETED AGENTS IS EFFECTIVE; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; STUDIED MACROPHAGES TO IMPROVE TREATMENT; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; AND SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK.IN 2023 ALONE, OCRA RESEARCHERS: IDENTIFIED A MOLECULE THAT COULD BE A KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; IDENTIFIED RNA-BINDING PROTEIN GENES AS ANOTHER POTENTIAL SOURCE OF HEREDITARY CANCERS, IN ADDITION TO MORE WELL-KNOWN GENES LIKE BRCA 1/2; SET OUT TO UNDERSTAND HOW CANCER SPREADS AND HOW CANCER CELLS RELY ON/DEPLOY ENERGY SOURCES LIKE SUGAR AND FAT TO SURVIVE TO FIND BETTER TREATMENTS; HIGHLIGHTED THE NEED FOR INDIVIDUAL ASSESSMENT OF COMPLEX VARIANTS TO CORRECTLY IDENTIFY INDIVIDUALS AT RISK; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; DISCOVERED A NEW APPROACH TO IMMUNOTHERAPY THAT OVERCOMES SOME OF THE CHALLENGES OF TREATING OVARIAN CANCER; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; PROVIDED AN OVERVIEW OF POTENTIAL THERAPEUTIC STRATEGIES THAT OBSTRUCT PLATELETS' PROTUMOR EFFECTS BY REPROGRAMMING THE TUMOR MICROENVIRONMENT; FOUND THAT MESOTHELIAL CELLS ARE IMPORTANT TO THE INITIAL STAGES OF OVARIAN CANCER GROWTH IN THE ABDOMINAL CAVITY; PROVIDED A NEW THERAPEUTIC STRATEGY TO OVERCOME TME-MEDIATED RESISTANCE TO PARPI ; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; AND UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE THAT CAN HELP EXPLAIN WHY OVARIAN CANCERS HAVE BEEN RESISTANT TO IMMUNOTHERAPY TO DATE. EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG. 586412 438937 EACH YEAR, OCRA BRINGS TOGETHER OVARIAN CANCER PATIENTS, SURVIVORS AND CAREGIVERS AT THE OVARIAN CANCER NATIONAL CONFERENCE, A THREE DAY-LONG EVENT FILLED WITH INFORMATIONAL SESSIONS FEATURING EXPERT SPEAKERS, FUN AND COMMUNITY. MORE THAN 605 PEOPLE FROM ALL AROUND THE WORLD COME TOGETHER VIRTUALLY FOR THIS EVENT. THE SPIRIT OF UNITY AND HOPE IS ALWAYS STRONG AND ATTENDEES CAN LEARN MORE ABOUT THEIR DIAGNOSIS, TREATMENT, AND SURVIVORSHIP. SESSIONS FEATURE TOP OVARIAN CANCER EXPERTS WHO GENEROUSLY GIVE OF THEIR TIME, PRESENTING THE LATEST IN TREATMENTS, RESEARCH, MANAGING RECURRENCE, GENETICS, NUTRITION, CARETAKER AND SUPPORTER CARE, SUPPORT FOR YOUNG WOMEN, ADVOCACY, AND SO MUCH MORE. 1854450 BEYOND OUR CONFERENCE, OCRA HAS ADDITIONAL PATIENT EDUCATION AND SUPPORT PROGRAMS AND ENGAGES IN ADVOCACY ON BEHALF OF WOMEN WITH GYNECOLOGIC CANCERS. OUR WEBSITE IS A COMPREHENSIVE SOURCE OF EDUCATIONAL INFORMATION, AND THROUGHOUT THE COURSE OF THE YEAR WE HOLD A SERIES OF FREE, EDUCATIONAL WEBINARS ON A RANGE OF TOPICS RELATED TO THE LATEST RESEARCH, TREATMENT, AND SURVIVORSHIP. OCRA'S PATIENT-SUPPORT LINE IS STAFFED BY OUR SOCIAL WORK TEAM DURING BUSINESS HOURS MONDAY THROUGH FRIDAY AND IS AVAILABLE TO ANYONE SEEKING INFORMATION, SUPPORT, PATIENT NAVIGATION, OR RESOURCE REFERRALS (MEDICAL ADVICE IS NOT PROVIDED). OUR WOMAN TO WOMAN PROGRAM IS A PEER-TO-PEER SUPPORT PROGRAM FOR WOMEN WITH GYNECOLOGIC CANCER. OCRA OFFERS BOTH A NATIONAL WOMAN TO WOMAN PROGRAM AND PROVIDES FINANCIAL SUPPORT TO HELP HOSPITALS AND OTHER ORGANIZATIONS START LOCAL WOMAN TO WOMAN PROGRAMS, WHICH ARE NOW AT MORE THAN 24 SITES ACROSS THE COUNTRY. OUR STAYING CONNECTED SUPPORT SERIES, WHICH LAUNCHED IN 2020, NOW OFFERS FOUR WEEKLY WORKSHOPS AND THREE MONTHLY WORKSHOPS WHICH ENABLES ALL IMPACTED BY OVARIAN OR RELATED GYNECOLOGIC CANCERS A WAY TO LEARN, SHARE, AND CONNECT. OUR ARTS PROGRAM, EXPRESS YOURSELF, OFFERS A COMBINATION OF THERAPEUTIC ARTS, POETRY, AND COMMUNITY BUILDING ACTIVITIES. OCRA PARTNERS WITH INSPIRE.COM TO OFFER AN ONLINE SUPPORT COMMUNITY THAT HAS OVER 80,000 MEMBERS WORLD-WIDE. OCRA IS COMMITTED TO ENCOURAGING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS TO FOCUS ON THE CRITICAL NEEDS OF THOSE DIAGNOSED WITH GYNECOLOGIC CANCER, WHETHER AT BENCH OR BEDSIDE. THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT, WE ACCEPT TOP MASTER OF SOCIAL WORK CANDIDATES TO TRAIN WITH OUR LICENSED CLINICAL SOCIAL WORKERS TO ADDRESS THE SPECIFIC NEEDS OF OUR COMMUNITY. OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. EACH YEAR, MORE THAN 1,000 SURVIVOR VOLUNTEERS DELIVERED PRESENTATIONS AT 405+ SCHOOLS IN 41 STATES (AS WELL AS UK, CANADA AND AUSTRALIA), AND REACH OVER 10,000 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS. OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER . EACH YEAR OCRA PLAYS A CRITICAL ROLE IN HELPING TO SECURE MORE THAN $200 MILLION IN FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION. IN ADDITION, OUR GROWING ADVOCATE LEADER PROGRAM TRAINS MEMBERS OF THE GYNECOLOGIC CANCER COMMUNITY TO RAISE AWARENESS THROUGH NEWS ARTICLES AND OUTREACH, DEVELOP RELATIONSHIPS WITH THEIR ELECTED OFFICIALS, AND FIGHT FOR INCREASED FUNDING FOR GYNECOLOGIC CANCER RESEARCH THROUGHOUT THE COUNTRY. 11116441 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 42 0 1 30 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 19 19 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CT FL GA HI IL KS KY MA MD MI MN MS ND NH NJ NM NY OR PA RI SC TN VA WI WV X X AUDRA MORAN 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 JOHN ORRICO CHAIR 3.00 X X 0 0 0 MATTHEW NEAL MILLER VICE PRESIDENT 2.00 X X 0 0 0 MARK TESSAR TREASURER 2.00 X X 0 0 0 ROBIN S COHEN SECRETARY 2.00 X X 0 0 0 JEANNETTE CHANG DIRECTOR 1.00 X 0 0 0 DR CARMEL J COHEN DIRECTOR 1.00 X 0 0 0 MEI-LI DA SILVA VINT ESQ DIRECTOR 1.00 X 0 0 0 ANDREW FEUERSTEIN DIRECTOR 1.00 X 0 0 0 CAROL J HAMILTON DIRECTOR 1.00 X 0 0 0 JOHN W HANSBURY ESQ DIRECTOR 1.00 X 0 0 0 CAROLINE HIRSCH DIRECTOR 1.00 X 0 0 0 VERONICA JORDAN DIRECTOR 1.00 X 0 0 0 THOMAS C LIEBMAN DIRECTOR 1.00 X 0 0 0 DANA L MARK ESQ DIRECTOR 1.00 X 0 0 0 YLAIN G MAYER DIRECTOR 1.00 X 0 0 0 CHRIS NEWCOMB DIRECTOR 1.00 X 0 0 0 LISA SCHREIBER DIRECTOR 1.00 X 0 0 0 ELLE SIMONE SCOTT DIRECTOR 1.00 X 0 0 0 CHRISTOPHER TILBERIS DIRECTOR 1.00 X 0 0 0 AUDRA L MORAN PRESIDENT & CEO 40.00 X 312816 0 32894 BIBI ALI CHIEF FINANCIAL OFFICER 40.00 X 202842 0 27511 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 40.00 X 204750 0 28594 SARAH DEFEO CHIEF PROGRAM OFFICER 40.00 X 183750 0 36476 TRACY MOORE VP - SUPPORT & EDUCATION 40.00 X 152500 0 25979 NICOLE WARGO VP - PHILANTHROPIC PARTNER 40.00 X 128823 0 25316 CHAD RAMSEY VP - POLICY 40.00 X 119107 0 24535 1304588 0 201305 8 0 1 0 0 1160499 10395812 2797584 11556311 CONFERENCE 900099 438937 438937 438937 1095100 1095100 24562455 24210288 352167 352167 352167 145898 1160499 145898 0 13442515 438937 0 1447267 7397910 7397910 720000 720000 576063 247748 241887 86428 1887757 983575 246307 657875 57486 30017 6823 20646 358801 185282 56396 117123 184609 92726 35344 56539 40512 40512 83213 83213 78481 78481 637844 423783 214061 103007 51503 19572 31932 303836 79546 41034 183256 277972 139621 53218 85133 156400 78558 29942 47900 56824 46336 10488 287193 287193 18366 9225 3516 5625 GENETIC TESTING 285602 285602 MISCELLANEOUS 103750 52112 19863 31775 CREDIT CARD CHARGES 87992 87992 BANK FEES 19480 19480 29662 5704 20480 3478 13752760 11116441 1220617 1415702 7221319 3782283 6857210 669631 72866 112347 223290 220915 14449 2375 22022779 34459485 1470465 177236 37659088 39203357 196109 247245 13020131 14388180 1612582 84868 14828822 14720293 X 20616851 13689736 2213415 10793328 22830266 24483064 37659088 39203357 -310245 1963043 0 X X 0 1 X 1 0 X 7042129 6224819 11263534 15386443 11556311 51473236 1600050 508436 395086 496688 584835 3585095 8642179 6733255 11658620 15883131 12141146 55058331 1034275 987693 1498020 876315 578139 4974442 703824 462162 2628087 6915041 4139569 14848683 1738099 1449855 4126107 7791356 4717708 19823125 35235206 674622 611749 542131 710226 1095100 3633828 674622 611749 542131 710226 1095100 3633828 9316801 7345004 12200751 16593357 13236246 58692159 0.60030 0.64180 0.06190 0.05630 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 13752760 13752760 837638 209410 0 0 567882 704647 723133 837638 2833300 4249950 973 973 141971 176162 180783 209410 708326 1062489 973 973 223290 220915 2375 2375 OPERATING LEASE OBLIGATION 84868 84868 X PART X, LINE 2: OCRA APPLIES THE PROVISIONS PERTAINING TO UNCERTAIN TAX POSITIONS OF FASB ASC TOPIC 740, INCOME TAXES, AND HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. OCRA IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIODS IN PROGRESS. OCRA BELEIVES IT IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR TAX PERIODS PRIOR TO 2020. 1 NORTH AMERICA 0 0 AWARDING OF GRANTS AWARDING OF RESEARCH GRANTS 720000 0 0 0 0 0 0 720000 0 720000 NORTH AMERICA RESEARCH GRANT 450000 0 NORTH AMERICA RESEARCH GRANT 270000 0 2 0 0 0 0 0 0 PART I, LINE 2: YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS ARE REQUIRED OVARIAN CYCLE 178798 159380 19418 2 1127599 1001119 126480 1306397 1160499 145898 145898 1 MD ANDERSON CANCER CENTER PO BOX 301429 HOUSTON TX 77230 746001118 501(C)(3) 1350000 0 RESEARCH GRANT DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 75000 0 RESEARCH GRANT CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD 65-WIL SUITE 1800 LOS ANGELES CA 90095 951644600 501(C)(3) 74954 0 RESEARCH GRANT UNIVERSITY OF COLORADO DENVER 13001 E 17TH PLACE RM W1124 AURORA CO 80045 846000555 501(C)(3) 426870 0 RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BUILDING 5TH FLOOR PHILADELPHIA PA 19104 231352685 501(C)(3) 650000 0 RESEARCH GRANT THE MEDICAL COLLEGE OF WISCONSIN 8701 W WATERTOWN PLANK RD MILWAUKEE WI 53226 390806261 501(C)(3) 75000 0 RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE CAMPUS BOX 1054 SAINT LOUIS MO 63130 430653611 501(C)(3) 75000 0 RESEARCH GRANT COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK WEST 168TH STREET NEW YORK NY 10032 135598093 501(C)(3) 900000 0 RESEARCH GRANT UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER 865 RESEARCH PARKWAY SUITE 530 OKLAHOMA CITY OK 73104 731563627 501(C)(3) 888314 0 RESEARCH GRANT GLOBAL COALITION FOR ADAPTIVE RESEARCH 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 94939 821199380 501(C)(3) 500000 0 RESEARCH GRANT NATIONAL FOUNDATION FOR CANCER RESEARCH 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 042531031 501(C)(3) 500000 0 RESEARCH GRANT WOMEN & INFANTS HOSPITAL OF RHODE ISLAND 101 DUDLEY STREET PROVIDENCE RI 02905 050258937 501(C)(3) 450000 0 RESEARCH GRANT OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 316025986 501(C)(3) 1333314 0 RESEARCH GRANT UNIVERSITY OF CHICAGO 6054 S DREXEL AVENUE - SUITE 300 CHICAGO IL 60637 362177139 501(C)(3) 450000 0 RESEARCH GRANT JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE SOM733 NORTH BROADWAY SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 450000 0 RESEARCH GRANT WEST MICHIGAN CANCER CENTER 200 N PARK STREET KALAMAZOO MI 49007 383061574 501(C)(3) 200000 0 RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 946036493 501(C)(3) 199638 0 RESEARCH GRANT UNIVERSITY OF CALIFORNIA LOS ANGELES 10889 WILSHIRE BOULEVARD SUITE 700 LOS ANGELES CA 90095 956006143 501(C)(3) 75000 0 RESEARCH GRANT 18 PART I, LINE 2: YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS ARE REQUIRED X X X 0 0 0 0 0 0 0 0 0 AUDRA L MORAN PRESIDENT & CEO 312816 0 0 0 0 0 12862 0 20032 0 345710 0 0 0 BIBI ALI CHIEF FINANCIAL OFFICER 202842 0 0 0 0 0 7566 0 19945 0 230353 0 0 0 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 204750 0 0 0 0 0 0 0 28594 0 233344 0 0 0 SARAH DEFEO CHIEF PROGRAM OFFICER 183750 0 0 0 0 0 7350 0 29126 0 220226 0 0 0 TRACY MOORE VP - SUPPORT & EDUCATION 152500 0 0 0 0 0 6100 0 19879 0 178479 0 0 0 NICOLE WARGO VP - PHILANTHROPIC PARTNER 128823 0 0 0 0 0 5153 0 20163 0 154139 0 0 0 X 17 2794584 FAIR MARKET VALUE 0 0 1 0 PART I, COLUMN (B): NUMBER OF CONTRIBUTIONS RECEIVED DURING THE YEAR FORM 990, PART I, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: OVARIAN CANCER RESEARCH ALLIANCE IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS, AUDIT COMMITTEE, TREASURER, CFO AND THE CEO, AND IS REVIEWED WITH THE EXTERNAL CPA PRIOR TO ITS FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C TO BE SIGNED BY ALL BOARD MEMBERS ANNUALLY FORM 990, PART VI, SECTION B, LINE 15 OCRA HAS A COMPENSATION COMMITTEE WHICH MEETS ANNUALLY TO REVIEW THE CEO, AND DETERMINE COMPENSATION, UTILIZING DATA FROM COMPARABLY-SIZED ORGANIZATIONS (OBTAINED FROM 990 FILINGS). SALARY INCREASES FOR KEY EMPLOYEES ARE RECOMMENDED BY THE CEO TO THE COMPENSATION COMMITTEE AFTER AN EVALUATION IS COMPLETED. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OCRA'S WEBSITE AND ALL OTHER DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XII, LINE 2C THE ORGANIZATION'S PROCESS FOR SELECTING AN INDEPENDENT ACCOUNTANT HAS NOT CHANGED FROM THE PRIOR YEAR. OVARIAN CANCER NATIONAL ALLIANCE 1101 14TH STREET NW WASHINGTON DC 20005 311581756 EDUCATION & ADVOCACY DC 501(C)(3) LINE 10 OVARIAN CANCER RESEARCH FUND INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0